Perth, Western Australia, 02 August 2019: Proteolytics Pty Ltd, a clinical-stage biotechnology company developing novel therapeutics for advanced wound care and skin disorders, today announced a proposed comparative in-vivo study of OPAL-A, its proprietary botanical extract from pawpaw fruit, to treat chronic wounds. The proposed study will be conducted at the National Research Council (CNR) of Italy in Milan.
Proteolytics Announces In-Vivo Study to Treat Chronic Wounds with OPAL-A Pawpaw Extract
Proteolytics Announces First Data from Treatment of Skin Irritation with OPAL-A Pawpaw Extract
22 July 2019